Company: SMNR
Filing Date: 2025-10-21
Form Type: S-1
Source: 0001193125-25-245178
Chunk: 279

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-10-21
Form: S-1
Chunk 279
---
 outstanding capital stock entitled to vote. At the time of the Chapter 11 filing, Dr. Ji, who serves as Semnur’s Executive Chairperson and a member of the Board, was and continues to serve as Chairman of the board of directors, President and Chief Executive Officer of Sorrento; Mr. Shah, who will serve as Semnur’s Chief Executive Officer, was serving as a director as Sorrento and served as a director until November 2023; Dr. Wu, who will serve on the Board, was serving as a director of Sorrento and served as a director until April 2024; and Mr. Followwill, who will serve on the Board, was serving as a director of Sorrento and served as a director until April 2024. Semnur does not expect that such proceedings will have a material effect. Composition of the Board Semnur’s business and affairs are managed under the direction of the Board, which consists of five members. Dr. Ji serves as Executive Chairperson of the Board. The primary responsibilities of the Board are to provide oversight, strategic guidance, counseling and direction to Semnur’s management. The Board meets on a regular basis and on an ad hocbasis as required. In accordance with the terms of the Charter and Bylaws, the Board is divided into three classes with staggered three-year terms, as follows:

| • |     | The Class I directors are Jay Chun, M.D., Ph.D. and Dr. Annu Navani and such director’s term will expire at the annual meeting of stockholders to be held in 2026; |

| • |     | The Class II directors will be Dorman Followwill and Yue Alexander Wu, Ph.D. and their term will expire at the annual meeting of stockholders to be held in 2027; and |

| • |     | The Class III directors will be Henry Ji, Ph.D. and Jaisim Shah and their term will expire at the annual meeting of stockholders to be held in 2028. |

**At each annual meeting of stockholders to be held after the initial classification, the successors to directors whose terms will expire will be elected to serve from the time of election and qualification until the third annual meeting following their election. The authorized number of directors that shall constitute the Board is determined 180

exclusively by the Board;provided that, at any time the Scilex Group beneficially owns, in the aggregate, at least 50% in